Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 2,293 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cardiac Ischemia Clear all

Conditions: Coronary Artery Disease
Interventions: Resolute Integrity Stent; Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Heart Defects, Congenital
Interventions: Remote Ischemic Preconditioning, Control; Procedure · Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 1 Day to 6 Months
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Cardiovascular Disease and Lipoprotein(a)
Interventions: TQJ230, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8,323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 287
States / cities: Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 136 more

Conditions: Myocardial Ischemia, Coronary Disease, Coronary Artery Disease, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases
Interventions: Myocardial Perfusion Imaging Study, AMMONIA N-13 37.5 mCi in 1 mL INTRAVENOUS INJECTION [Ammonia N 13]; Diagnostic Test · Drug
Lead sponsor: Ionetix Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Miami, Florida • Miami Beach, Florida • Jenkintown, Pennsylvania + 2 more

Conditions: Coronary Artery Disease
Interventions: Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: BSP Biological Signal Processing Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Cleveland, Ohio • Charlottesville, Virginia

Conditions: Myocardial Infarction, Arrhythmia, Ventricular, Ischemic Cardiomyopathy
Interventions: T Wave Alternans Test; Procedure
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: Not listed
Enrollment: 405 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 47
States / cities: Mobile, Alabama • Phoenix, Arizona • Walnut Creek, California + 44 more

Conditions: Acute Coronary Syndrome
Interventions: Iodofiltic acid I 123; Drug
Lead sponsor: Molecular Insight Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 36
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 33 more

Conditions: Atrial Fibrillation
Interventions: Catheter ablation; Procedure
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Larkspur, California • Boulder, Colorado + 7 more

Conditions: Coronary Artery Disease
Interventions: Early Bird® Bleed Monitoring System, Impella®; Device
Lead sponsor: Saranas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 11
States / cities: Phoenix, Arizona • Tucson, Arizona • Gary, Indiana + 7 more

Conditions: Coronary Artery Disease
Interventions: SpartanRX; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hypercholesterolemia, Coronary Heart Disease
Interventions: Mipomersen, Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Jupiter, Florida • Winter Park, Florida • Atlanta, Georgia + 6 more

Conditions: Coronary Artery Disease
Interventions: Etomidate, Propofol; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Acute Coronary Syndrome
Interventions: Milvexian, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14,194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 162
States / cities: Alexander City, Alabama • Birmingham, Alabama • Mobile, Alabama + 141 more

Conditions: Myocardial Infarction, Stroke, Ischemic, Ischemia
Interventions: There is no intervention given to the subjects; Other
Lead sponsor: UConn Health; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: Sapere Bio; Industry
Eligibility: 50 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stroke, Ischemic, Device Related Thrombosis, Atrial Fibrillation
Interventions: Watchman FLX left atrial appendage occlusion; Device
Lead sponsor: Aarhus University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Disease
Interventions: Omacor (omega-3-acid ethyl esters); Drug
Lead sponsor: Olive View-UCLA Education & Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Sylmar, California

Conditions: Neutrophils.Hypersegmented &#X7C; Bld-Ser-Plas, STEMI - ST Elevation Myocardial Infarction
Interventions: Colchicine Pill; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 19 Years to 110 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease
Interventions: Nicardipine, Sterile Saline; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Platelet Aggregation, Platelet Transcriptome, Coronary Artery Disease
Interventions: Clopidogrel, Aspirin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Coronary Syndrome (ACS), Myocardial Infarction
Interventions: Telehealth-enhanced Hybrid CR, Traditional Cardiac Rehabilitation; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Artery Disease (CAD)
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Heart Attack, Cardiovascular Diseases
Interventions: Stress Management and Resiliency Training Program; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System

Neuroprotective Effects of Remote Ischemic Preconditioning (RIPC) During Infant Cardiac Surgery

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)

Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications. Is a Picture Really Worth a Thousand Words?

Detection of Coronary Artery Disease Using Analysis of High Frequency QRS: The HyperQ Registry

MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

Posterior Wall And Left Atrial Appendage Empiric Electrical Isolation for Non-Paroxysmal Atrial Fibrillation

Safe Surveillance of PCI Under Mechanical Circulatory Support With the Saranas Early Bird Bleed Monitoring System

Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy

Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis

Etomidate Versus Propofol in CABG Surgery

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Study of Circulating Monocytes in Patients With Ischemic Vascular Disease

The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery

APPEND-CT Registry

The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease

CLEAR SYNERGY Neutrophil Substudy

Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine

Pharmacogenomics of Antiplatelet Response - I

TeleheartCR vs. Clinic-Based Cardiac Rehabilitation After Acute Coronary Syndrome

Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants

Stress Management and Resiliency Training Following Acute Myocardial Infarction